Inhibition Effects of Hepatocellular Carcinoma Developments for Interferon-Free, Direct-Acting Antiviral Agents for Hepatitis C Virus

Inhibition Effects of Hepatocellular Carcinoma Developments for Interferon-Free, Direct-Acting Antiviral Agents for Hepatitis C Virus - DAAs for HCV and Hepatocellular Carcinoma Developments

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015933

Enrollment

700

Registered

2014-12-13

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the patients with infected Hepatitis C virus(HCV)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The DAAs group who achieved sustained viral response (SVR) by DAAs, such as sofosbuvir, ledipasvir and ribavirin. The IFN group who achieved sustained viral response (SVR) by PegIFN/RBV/Protease inhibitor, such as Telaprevir(TVR) Simeprevir (SMV) or Vaniprevir (VAN)

Exclusion criteria

Exclusion criteria: non SVR IFN without Protease inhibitor

Design outcomes

Primary

Measure	Time frame
The periods and numbers of HCC developments	—

Countries

Japan

Contacts

Public ContactMasaaki Korenaga

National Center for Global Health and Medicine (NCGM) The Research Center for Hepatitis and Immunology

dmkorenaga@hospk.ncgm.go.jp047-372-3501

Outcome results